ClinicalTrials.gg
CompletedNCT05899829Updated Dec 4, 2024Results posted

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

A Phase 1 interventional study of Camlipixant and Rabeprazole in Cough and Healthy, sponsored by Bellus Health Inc. - a GSK company. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BLU-5937 in Cough — 1 open to participants now, 2 under way, 2 of them phase 3. BLU-5937 · Cough.

Enrollment
6th of 10
42 · median 44
Started
2023
with 1 other
Phase 1
7 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
8 of 10
Bellus Health Inc. - a GSK company

Among the 10 studies testing BLU-5937 in Cough, this one is the 6th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 5th registered.

Cough

428 studies on the registry are indexed under Cough; 68 are open to participants now.

Browse Cough studies →

Open to participants now

1 of the 10 studies testing BLU-5937 in Cough is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About BLU-5937

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing BLU-5937 in Cough, or all of them as a file.
02

Study summary

This is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin (part 1) and rabeprazole (part 2) on the pharmacokinetics of a single dose of camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.

03

Conditions studied

  • Cough
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or non-pregnant, non-lactating healthy females

Exclusion criteria

Exclusion Criteria:

  • History of history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disorder, as judged by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part 1: Camlipixant 50 mg + Rifampin 600 mg

    Participants will receive a single oral dose of camlipixant 50 milligram (mg) tablet on Day 1, followed by repeat oral doses (2\*300 mg) of rifampin 600 mg capsules, once daily (QD) from Days 4 to 12, with co-administration of a single oral dose of 50 mg camlipixant tablet with rifampin capsules on Day 11. There will be a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rifampin on Day 4.

    Drug: Camlipixant · Drug: Rifampin

  • Experimental
    Part 2: Camlipixant 50 mg + Rabeprazole 20 mg

    Participants will receive a single oral dose of camlipixant 50 mg tablet on Day 1, followed by repeat oral doses of 20 mg rabeprazole enteric-coated tablets, once daily (QD) from Days 4 to 11, with co-administration of a single oral dose of 50 mg camlipixant tablet with rabeprazole enteric-coated tablet on Day 10. There will be a washout of at least 3 days between the dose of camlipixant on Day 1 and the dose of rabeprazole on Day 4

    Drug: Camlipixant · Drug: Rabeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-Infinity]) of Camlipixant

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  2. Part 2: AUC(0-Infinity) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

  3. Part 1: Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  4. Part 2: AUC(0-t) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

  5. Part 1: Maximum Observed Concentration (Cmax) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  6. Part 2: Cmax of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

Secondary outcomes

  1. Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  2. Part 2: Tmax of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

  3. Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  4. Part 2: T1/2 Following Administration of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

  5. Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (% AUC Extrapolation) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  6. Part 2: % AUC Extrapolation of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

  7. Part 1: Terminal Elimination Rate Constant of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  8. Part 2: Terminal Elimination Rate Constant of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

  9. Part 1: Apparent Clearance (CL/F) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  10. Part 2: CL/F of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

  11. Part 1: Apparent Oral Volume of Distribution (Vz/F) of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11

  12. Part 2: Vz/F of Camlipixant

    Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10

  13. Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

    Time frame: Up to Day 22 for Part1 (Day1 post-dose until Day4 pre-dose of rifampin [Camlipixant 50mg];From Day4 dosing until Day11 pre-dose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study [Day 22] [Camlipixant 50mg+Rifampin 600mg]

  14. Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs

    An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

    Time frame: Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg]

  15. Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings

    A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

    Time frame: Day 4, Day 11, and Day 13

  16. Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings

    A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

    Time frame: Day 4, Day 10, and Day 12

  17. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate

    Vital signs including diastolic blood pressure (DBP), systolic Blood Pressure (SBP), and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Day 11 and Day 13

  18. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate

    Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Day 10 and Day 12

  19. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature

    Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Day 13

  20. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature

    Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Day 12

  21. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination

    Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

    Time frame: Up to Day 13

  22. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination

    Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

    Time frame: Up to Day 12

  23. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters

    Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

    Time frame: Up to Day 13

  24. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters

    Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

    Time frame: Up to Day 12

  25. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters

    Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

    Time frame: Up to Day 13

  26. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters

    Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

    Time frame: Up to Day 12

  27. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters

    Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international (Intl.) normalized ratio, and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

    Time frame: Up to Day 13

  28. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters

    Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international (Intl.) normalized ratio, and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

    Time frame: Up to Day 12

  29. Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis

    Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

    Time frame: Up to Day 13

  30. Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis

    Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

    Time frame: Up to Day 12

07

Results

Posted Dec 4, 2024

Participant flow

Part 1 (Up to Day 22)
Participant flow — Part 1 (Up to Day 22)
MilestonePart 1: Camlipixant 50 mg + Rifampin 600 mgPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Started200
Safety population160
Completed160
Not completed40
Withdrew: Enrolled but did not receive study treatment40
Part 2 (up to Day 21)
Participant flow — Part 2 (up to Day 21)
MilestonePart 1: Camlipixant 50 mg + Rifampin 600 mgPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Started022
Safety population016
Completed016
Not completed06
Withdrew: Enrolled but did not receive study treatment06

Outcome measures

PrimaryPart 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-Infinity]) of Camlipixant

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-Infinity]) of Camlipixant
Hours*nanograms per milliliterPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 13851.24 ± 39.27
Day 111423.84 ± 38.90
PrimaryPart 2: AUC(0-Infinity) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: AUC(0-Infinity) of Camlipixant
Hours*nanograms per milliliterPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 15425.54 ± 29.55
Day 105514.74 ± 33.39
PrimaryPart 1: Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t]) of Camlipixant
Hours*nanograms per milliliterPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 13834.41 ± 39.31
Day 111419.39 ± 38.97
PrimaryPart 2: AUC(0-t) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: AUC(0-t) of Camlipixant
Hours*nanograms per milliliterPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 15403.91 ± 29.52
Day 105474.24 ± 33.07
PrimaryPart 1: Maximum Observed Concentration (Cmax) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Geometric mean · Nanograms per milliliter
Part 1: Maximum Observed Concentration (Cmax) of Camlipixant
Nanograms per milliliterPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 1819 ± 19.54
Day 11519 ± 27.84
PrimaryPart 2: Cmax of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Nanograms per milliliter
Part 2: Cmax of Camlipixant
Nanograms per milliliterPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 11080 ± 24.74
Day 10912 ± 34.29
SecondaryPart 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Median · Hours
Part 1: Time to Reach Maximum Observed Concentration (Tmax) of Camlipixant
HoursPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 11.000 (0.250 to 2.500)
Day 110.750 (0.500 to 3.000)
SecondaryPart 2: Tmax of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Median · Hours
Part 2: Tmax of Camlipixant
HoursPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 10.750 (0.500 to 1.000)
Day 101.750 (0.600 to 4.017)
SecondaryPart 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Geometric mean · Hours
Part 1: Terminal Elimination Half-Life (T1/2) Following Administration of Camlipixant
HoursPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 15.05 ± 32.02
Day 111.94 ± 28.68
SecondaryPart 2: T1/2 Following Administration of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Hours
Part 2: T1/2 Following Administration of Camlipixant
HoursPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 16.01 ± 16.90
Day 106.78 ± 17.01
SecondaryPart 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (% AUC Extrapolation) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Geometric mean · Percentage of AUC extrapolation
Part 1: Percentage of AUC0-Infinity Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (% AUC Extrapolation) of Camlipixant
Percentage of AUC extrapolationPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 10.40 ± 45.60
Day 110.30 ± 33.74
SecondaryPart 2: % AUC Extrapolation of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods. Percentage of AUC extrapolation was calculated as \[1 - (AUC0-t/AUC0-inf)\] \* 100.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Percentage of AUC extrapolation
Part 2: % AUC Extrapolation of Camlipixant
Percentage of AUC extrapolationPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 10.34 ± 54.00
Day 100.57 ± 84.03
SecondaryPart 1: Terminal Elimination Rate Constant of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Geometric mean · Per hour
Part 1: Terminal Elimination Rate Constant of Camlipixant
Per hourPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 10.1372 ± 32.02
Day 110.3579 ± 28.68
SecondaryPart 2: Terminal Elimination Rate Constant of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Per hour
Part 2: Terminal Elimination Rate Constant of Camlipixant
Per hourPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 10.1153 ± 16.90
Day 100.1022 ± 17.01
SecondaryPart 1: Apparent Clearance (CL/F) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Geometric mean · Liters per hour
Part 1: Apparent Clearance (CL/F) of Camlipixant
Liters per hourPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 112.98 ± 39.27
Day 1135.12 ± 38.90
SecondaryPart 2: CL/F of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Liters per hour
Part 2: CL/F of Camlipixant
Liters per hourPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 19.22 ± 29.55
Day 109.07 ± 33.39
SecondaryPart 1: Apparent Oral Volume of Distribution (Vz/F) of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 11
Reported as:
Geometric mean · Liters
Part 1: Apparent Oral Volume of Distribution (Vz/F) of Camlipixant
LitersPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 194.66 ± 26.40
Day 1198.11 ± 29.90
SecondaryPart 2: Vz/F of Camlipixant

Blood samples were collected at indicated time points for PK analysis of Camlipixant. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Pre-dose, 0.16, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18, 24, 36, and 48 hours post-dose on Day 1 and Day 10
Reported as:
Geometric mean · Liters
Part 2: Vz/F of Camlipixant
LitersPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 179.96 ± 31.72
Day 1088.74 ± 26.78
SecondaryPart 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs)

An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

Time frame:
Up to Day 22 for Part1 (Day1 post-dose until Day4 pre-dose of rifampin [Camlipixant 50mg];From Day4 dosing until Day11 pre-dose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study [Day 22] [Camlipixant 50mg+Rifampin 600mg]
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Treatment-emergent Adverse Events of Medical Interest (TEAEMIs)
ParticipantsPart 1: Camlipixant 50 mgPart 1: Rifampin 600 mgPart 1: Camlipixant 50 mg+ Rifampin 600 mg
TEAEs3142
TESAEs000
TEAEMIs000
SecondaryPart 2: Number of Participants With TEAEs, TESAEs and TEAEMIs

An adverse event (AE) is defined as any untoward medical occurrence in a participant who is administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. Serious adverse events (SAEs) are defined as any untoward medical occurrence that; at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Adverse events of medical interest (AEMIs) are AEs of scientific interest specific to the drug class. Treatment-emergent events (i.e., TEAEs, TESAEs and TEAEMIs) were defined as events that commence on or after the time of first study drug administration.

Time frame:
Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg]
Reported as:
Count of participants · Participants
Part 2: Number of Participants With TEAEs, TESAEs and TEAEMIs
ParticipantsPart 2: Camlipixant 50 mgPart 2 : Rabeprazole 20 mgPart 2: Camlipixant 50 mg+ Rabeprazole 20 mg
TEAEs430
TESAEs000
TEAEMIs000
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings

A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

Time frame:
Day 4, Day 11, and Day 13
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead Electrocardiogram (ECG) Findings
ParticipantsPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 40
Day 110
Day 130
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings

A 12-lead ECG was recorded with the participant in a semi-recumbent or supine position, after 5 minutes of rest using an ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant 12-Lead ECG findings have been presented.

Time frame:
Day 4, Day 10, and Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in 12-Lead ECG Findings
ParticipantsPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 40
Day 100
Day 120
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate

Vital signs including diastolic blood pressure (DBP), systolic Blood Pressure (SBP), and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Day 11 and Day 13
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Diastolic Blood Pressure (DBP), Systolic Blood Pressure (SBP), and Heart Rate
ParticipantsPart 1: Camlipixant 50 mg + Rifampin 600 mg
Day 110
Day 130
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate

Vital signs including DBP, SBP, and heart rate were measured in a sitting position after resting for at least 5 minutes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Day 10 and Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: DBP, SBP, and Heart Rate
ParticipantsPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Day 100
Day 120
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature

Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Day 13
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature
ParticipantsPart 1: Camlipixant 50 mg + Rifampin 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature

Vital signs including respiratory rate and oral temperature were measured after resting for at least 5 minutes in a sitting position. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature
ParticipantsPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Vital Signs: Respiratory Rate and Oral Temperature0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination

Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination
ParticipantsPart 1: Camlipixant 50 mg + Rifampin 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination

Physical examination included assessment of the head, eyes, ears, nose, throat, neck, chest, lungs, abdomen, musculoskeletal, dermatological, cardiovascular/peripheral vascular, and general neurological examination. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for the number of participants with abnormal clinically significant changes in physical examination has been presented.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination
ParticipantsPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Physical Examination0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters

Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters
ParticipantsPart 1: Camlipixant 50 mg + Rifampin 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters

Blood samples were collected to analyze hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Hematocrit, Hemoglobin, Platelets, and Erythrocytes. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of participants with abnormal clinically significant changes in hematology parameters were reported.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters
ParticipantsPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Hematology Parameters0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters

Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters
ParticipantsPart 1: Camlipixant 50 mg + Rifampin 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters2
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters

Blood samples were collected to analyze clinical chemical parameters: albumin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, calcium, chloride, creatinine kinase, creatinine, gamma glutamyl transferase, glucose, phosphate, potassium, sodium, total, direct, and indirect bilirubin, protein, urea, and urate. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in clinical chemistry parameters were reported.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters
ParticipantsPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Clinical Chemistry Parameters0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters

Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international (Intl.) normalized ratio, and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters
ParticipantsPart 1: Camlipixant 50 mg + Rifampin 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters

Blood samples were collected to analyze coagulation parameters: activated partial thromboplastin time, prothrombin time international (Intl.) normalized ratio, and prothrombin time. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in coagulation parameters were reported.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters
ParticipantsPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Coagulation Parameters0
SecondaryPart 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis

Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

Time frame:
Up to Day 13
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis
ParticipantsPart 1: Camlipixant 50 mg + Rifampin 600 mg
Part 1: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis0
SecondaryPart 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis

Urine samples were collected to analyze urinalysis parameters: specific gravity and potential of hydrogen (pH). Bilirubin, blood (occult), glucose, ketones, leukocyte esterase, nitrite, protein, urobilinogen were analyzed by dipstick. The dipstick test gives results in a semi-quantitative manner, and results can be read as Negative, Trace, 1+, 2+ indicating proportional concentrations in the urine sample. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Number of Participants with abnormal clinically significant changes in urinalysis parameters were reported.

Time frame:
Up to Day 12
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis
ParticipantsPart 2: Camlipixant 50 mg + Rabeprazole 20 mg
Part 2: Number of Participants With Abnormal Clinically Significant Changes in Urinalysis0

Adverse events

Collected over Upto Day22 for Part1(Day1 postdose until Day4 predose of rifampin[Camlipixant 50mg];From Day4 dosing until Day11 predose of camlipixant [Rifampin 600mg];From camlipixant dosing on Day11 until end of study[Day22] [Camlipixant 50mg+Rifampin 600mg]. Upto Day21 for Part2(Day1 postdose until Day4 predose of rabeprazole [Camlipixant 50mg];From Day4 dosing until Day10 predose of camlipixant [Rabeprazole 20mg];From camlipixant dosing on Day10 until end of study[Day21] [Camlipixant 50mg+Rabeprazole 20mg]. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Camlipixant 50 mg0/16 (0%)0/16 (0%)3/16 (18.8%)
Part 1: Rifampin 600 mg0/16 (0%)0/16 (0%)14/16 (87.5%)
Part 1: Camlipixant 50 mg+ Rifampin 600 mg0/16 (0%)0/16 (0%)2/16 (12.5%)
Part 2: Camlipixant 50 mg0/16 (0%)0/16 (0%)4/16 (25%)
Part 2 : Rabeprazole 20 mg0/16 (0%)0/16 (0%)3/16 (18.8%)
Part 2: Camlipixant 50 mg+ Rabeprazole 20 mg0/16 (0%)0/16 (0%)0/16 (0%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPart 1: Camlipixant 50 mgPart 1: Rifampin 600 mgPart 1: Camlipixant 50 mg+ Rifampin 600 mgPart 2: Camlipixant 50 mgPart 2 : Rabeprazole 20 mgPart 2: Camlipixant 50 mg+ Rabeprazole 20 mg
ChromaturiaRenal and urinary disorders0/1613/160/160/160/160/16
PollakiuriaRenal and urinary disorders1/162/160/160/160/160/16
Alanine aminotransferase increasedInvestigations0/162/160/160/160/160/16
Urinary retentionRenal and urinary disorders0/161/160/160/160/160/16
Dry mouthGastrointestinal disorders0/161/161/160/160/160/16
Abdominal distensionGastrointestinal disorders0/160/161/160/160/160/16
Abdominal pain lowerGastrointestinal disorders1/160/160/160/160/160/16
ConstipationGastrointestinal disorders0/161/160/160/160/160/16
DyspepsiaGastrointestinal disorders0/161/160/160/160/160/16
NauseaGastrointestinal disorders1/160/160/160/160/160/16

Baseline characteristics

Baseline characteristics are reported for the Safety Population which consisted of all participants who received at least one dose of any study drug.

Age, Customized
Age, Customized(Participants)Part 1: Camlipixant 50 mg + Rifampin 600 mgPart 2: Camlipixant 50 mg + Rabeprazole 20 mgTotal
18 to 55 years161632
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Camlipixant 50 mg + Rifampin 600 mgPart 2: Camlipixant 50 mg + Rabeprazole 20 mgTotal
Female156
Male151126
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Camlipixant 50 mg + Rifampin 600 mgPart 2: Camlipixant 50 mg + Rabeprazole 20 mgTotal
Others112
White151530
08

Study locations

1 site
  • GSK Investigational Site
    Quebec City, Quebec G1P 0A2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Aug 2023, 1 month.

Results were first posted in Dec 2024, 1 year 3 months after primary completion.

Of 21 phase 1 interventional studies under Cough, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jun 12, 2023
StartActual
Jun 21, 2023
Primary completionActual
Aug 8, 2023
CompletionActual
Aug 8, 2023
Results first posted
Dec 4, 2024
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05899829
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Jun 21, 2023
Primary completion
Aug 8, 2023
Completion
Aug 8, 2023
Results posted
Dec 4, 2024
Last update
Dec 4, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion